Cancer Genetics Complete::IO Immuno-Oncology Panel

Cancer Genetics has expanded its immuno-oncology panel, Complete::IO, to include five new markers, bringing the total to 27. The test is a multi-marker panel for characterization of the immune repertoire of cancer patients, including circulating immune cell populations and the tumor microenvironment.

The assay is designed to help identify patients who are likely to respond to specific therapies, as well as to monitor and stratify patient populations during clinical trials. The five new markers now allow the test to detect myeloid-derived suppressor cells, as well as those that express PD-1, PD-L1, or PD-L2.